Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™
Cerenome presented new preclinical data at the Rivkin Ovarian Cancer Research Symposium showing REYOBIQ (rhenium-186 nanoliposome) has a dual mechanism: direct lethal DNA damage within 24 hours plus immunomodulatory effects that reduce immunosuppressive signaling such as IL-10. In mouse models of aggressive epithelial ovarian cancer, 186RNL combined with anti-PD-1 checkpoint blockade extended median survival to 65 days, longer than either agent alone, with CD8+ T-cell-dominant immune activation and no substantial added toxicity.
Key figures
- Drug Name
- REYOBIQ (rhenium Re186 obisbemeda / 186RNL)
- Phase Of Trial
- Preclinical (lead asset in Phase 1 ReSPECT-GBM)
- Dose range mci
- 0.075 to 1.257
- Dose response p value
- p = 0.0003
- Combination median survival days
- 65
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.